Isec Healthcare Ltd · SGX:40T
Isec Healthcare — H1 2018 Earnings Presentation
20 slides from Isec Healthcare's earnings presentation, Aug 8, 2018
Slide 1: Corporate Presentation – 6 months ended 30 June 2018
Corporate Presentation 6 months ended 30 June 2018 Page 0
Slide 2: Sponsor disclaimer
This presentation has been prepared by the Company and its contents have been reviewed by the Company’s sponsor, PrimePartners Corporate Finance Pte. Ltd. (the “Sponsor”), for compliance with the Singapore Exchange Securities Trading Limited (the “SGX-ST”) Listing Manual Section B: Rules of Catalist
Slide 3: Table of Content
Table of Content Business Overview Competitive Strengths of the Group Business Strategy and Expansion Plans Corporate Developments and Use of Proceeds 6 months Financial Highlights for the Period Ended 30 June 2018 Page 2
Slide 4: Business Overview
Business Overview Page 3
Slide 5: Business Overview
Business Overview • Specialised Health Services – Medical eye care service provider • ISEC is a comprehensive medical eye care service provider, with ambulatory surgical centres in Malaysia (Kuala Lumpur, Penang, Malacca & Sibu) and provides specialist medical ophthalmology services to Lee Hung Ming
Slide 6: Competitive Strengths of the Group
Competitive Strengths of the Group Page 5
Slide 7: Competitive Strengths of the Group
Competitive Strengths of the Group 1 Highly qualified and experienced specialist doctors 6 Business model aligns the 2 interests of our High quality and specialist doctors with comprehensive range of our Group and eye care services Shareholders 5 Ability to replicate our 3 Well positioned to busines
Slide 8: Business Strategy and Expansion Plans
Business Strategy And Expansion Plans Page 7
Slide 9: Our Business Strategies
Our Business Strategies To reach out to more patients in locations where we currently operate, as well as new locations such as major Growing the ISEC cities or locations in Peninsular Malaysia, East Malaysia and Brand and Singapore Expanding into To expand via setting up of subsidiaries, joint
Slide 10: Expansion Plans: Business expansion in the Asia Pacific
Expansion Plans Business expansion in the Asia Pacific region (including Malaysia Malaysia & and Singapore) Singapore Target Countries Page 9
Slide 11: Corporate Developments and Use of Proceeds
Corporate Developments And Use of Proceeds Page 10
Slide 12: Corporate Developments
Corporate Developments On 15 May 2018, the Company, through its wholly-owned subsidiary, ISEC Global Pte. Ltd., entered into a joint venture agreement with 3 independent third parties, namely Next Tier International Company Limited, Daw Pyae Pyae Thein and Dr. Khin Khin Win (collectively, the “JV Pa
Slide 13: Use of Proceeds as at 8 August 2018
Use of Proceeds As at 8 August 2018 Amount allocated pursuant to reallocation of Use of proceeds Amount allocated unutilised listing Amount S$’000 expenses utilised Balance S$’000 S$’000 S$’000 Business expansion in Asia Pacific region (including Malaysia 13,800 300 (12,579) (N1) 1,521 and Singapore
Slide 14: 6 Months Financial Highlights
6 Months Financial Highlights for the Period Ended 30 June 2018 Page 13
Slide 15: Revenue
Revenue SGD’mil 6M2018 vs 6M2017 The increase in Group revenue was mainly attributable to increased patient visits from the Group’s specialised eye care services in Malaysia and Singapore. Page 14
Slide 16: Revenue – Malaysia
Revenue – Malaysia RM’mil SGD’mil 8.2% 13.5% Revenue from Malaysia operations in Ringgit Malaysia (“RM”) increased from RM41.5 million in 6M2017 to RM44.9 million in 6M2018, up 8.2% mainly due to increased number of patients visits. Singapore Dollar translated revenue from Malaysia operations in 6
Slide 17: EBITDA and Profit After Tax (PAT)
Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) and Profit After Tax (PAT) SGD’000 EBITDA was S$6.4 million in 6M2018 as compared to S$5.4 million in 6M2017, an increase of S$1.0 million mainly due to increased patient visits from the Group’s specialised eye care services in
Slide 18: Cash Position
Cash Position Total cash and cash equivalents Unutilised IPO proceeds Cash balances SGD’mil Total cash and cash equivalents as at 30 June 2018 was S$26.0 million. No debt. Cash balances (exclude unutilised IPO proceeds) increased from S$23.3 million as at 31 December 2017 to S$24.5 million as at
Slide 19: Statement of Financial Position
Statement of Financial Position S$’000 30 June 31 December 2018 2017 Key Assets Plant and equipment 3,856 3,894 Intangible assets 38,800^ 38,766^ Trade and other receivables 3,096 2,505 Cash and cash equivalents 26,020 24,824 Key Liabilities Trade and other payables 3,508 3,475 Equity Total equity (
Slide 20: Thank You
Thank You Page 19